REGENERON PHARMACEUTICALS, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
REGENERON PHARMACEUTICALS, INC. (REGN) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-08.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2018-02-08
- REGENERON PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was -$15.65M, a 119.83% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-03-31 was $15.65M, a 90.78% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00.
- REGENERON PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $405.32M, a 7.73% decline from fiscal 2014.
- REGENERON PHARMACEUTICALS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $439.28M, a 107.30% increase from fiscal 2013.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-08 | |||||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $0.00 derived: sum of 2 quarters · filed 2018-02-08 | -$15.65M derived: sum of 3 quarters · filed 2018-02-08 | $0.00 10-K · filed 2018-02-08 | ||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$15.65M derived: sum of 2 quarters · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | $99.77M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | -$15.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | $99.77M derived: sum of 3 quarters · filed 2018-02-08 | $156.60M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $15.65M 10-Q · filed 2016-05-05 | $115.42M derived: sum of 2 quarters · filed 2018-02-08 | $172.25M derived: sum of 3 quarters · filed 2018-02-08 | $251.17M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $99.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $156.60M derived: sum of 2 quarters · filed 2018-02-08 | $235.52M derived: sum of 3 quarters · filed 2018-02-08 | $405.32M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $56.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $135.76M derived: sum of 2 quarters · filed 2016-11-04 | $305.55M 10-Q · filed 2016-11-04 | $410.68M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $78.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $248.72M 10-Q · filed 2016-08-04 | $353.85M derived: sum of 3 quarters · filed 2017-02-09 | $452.42M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $169.79M 10-Q · filed 2016-05-05 | $155.57M 10-Q · filed 2015-05-07 | $274.93M derived: sum of 2 quarters · filed 2017-02-09 | $373.50M derived: sum of 3 quarters · filed 2017-02-09 | $491.81M derived: sum of 4 quarters · filed 2017-02-09 | |||
| 2014-12-31 | $105.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $203.70M derived: sum of 2 quarters · filed 2017-02-09 | $322.02M derived: sum of 3 quarters · filed 2017-02-09 | $439.28M 10-K · filed 2017-02-09 | $448.56M 10-K · filed 2015-02-12 | |||
| 2014-09-30 | $98.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $216.89M derived: sum of 2 quarters · filed 2015-11-04 | $334.15M 10-Q · filed 2015-11-04 | $343.53M 10-Q · filed 2014-11-04 | $448.21M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-06-30 | $118.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $235.57M 10-Q · filed 2015-08-04 | $244.20M 10-Q · filed 2014-08-05 | $349.64M derived: sum of 3 quarters · filed 2016-02-11 | $439.61M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-03-31 | $117.26M 10-Q · filed 2015-05-07 | $231.33M derived: sum of 2 quarters · filed 2016-02-11 | $321.29M derived: sum of 3 quarters · filed 2016-02-11 | $326.88M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $114.07M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $204.03M derived: sum of 2 quarters · filed 2016-02-11 | $209.62M derived: sum of 3 quarters · filed 2016-02-11 | $211.91M 10-K · filed 2016-02-11 | $216.86M 10-K · filed 2014-02-13 | |||
| 2013-09-30 | $89.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $95.55M derived: sum of 2 quarters · filed 2014-11-04 | $97.84M 10-Q · filed 2014-11-04 | |||||
| 2013-06-30 | $5.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $7.88M 10-Q · filed 2014-08-05 | ||||||
| 2013-03-31 | $2.29M 10-Q · filed 2014-05-08 | |||||||
| 2012-12-31 | $4.31M 10-K · filed 2015-02-12 | |||||||
| 2011-12-31 | $0.00 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |